Dimensional Fund Advisors LP raised its position in shares of GSK plc (NYSE:GSK - Free Report) by 0.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,598,570 shares of the pharmaceutical company's stock after buying an additional 18,492 shares during the quarter. Dimensional Fund Advisors LP owned 0.13% of GSK worth $87,884,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Indiana Trust & Investment Management Co lifted its position in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares in the last quarter. Crews Bank & Trust purchased a new stake in shares of GSK during the fourth quarter worth $26,000. ST Germain D J Co. Inc. boosted its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sierra Ocean LLC purchased a new position in GSK in the fourth quarter valued at about $32,000. Finally, Parkside Financial Bank & Trust increased its position in GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 818 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, BNP Paribas started coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, GSK currently has an average rating of "Moderate Buy" and an average target price of $40.58.
Read Our Latest Analysis on GSK
GSK Stock Performance
Shares of NYSE GSK traded up $0.04 during trading hours on Monday, hitting $39.11. 393,686 shares of the stock were exchanged, compared to its average volume of 4,727,192. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company's 50 day moving average is $37.68 and its 200 day moving average is $36.00. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $80.70 billion, a P/E ratio of 24.61, a P/E/G ratio of 1.12 and a beta of 0.51.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. On average, research analysts expect that GSK plc will post 4.14 EPS for the current year.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.31%. GSK's payout ratio is 86.60%.
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
